Literature DB >> 1585377

Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells.

H S Yoo1, W P Norred, E Wang, A H Merrill, R T Riley.   

Abstract

Fumonisins are a group of structurally related compounds produced by Fusarium moniliforme. Recently, it has been shown that fumonisins B1 and B2 are the first naturally occurring inhibitors of sphingosine and sphinganine N-acyltransferase (ceramide synthase) in rat primary hepatocytes (Wang et al. J. Biol. Chem. 266, 14, 486-14, 490, 1991). These enzymes are key components in the pathways for de novo sphingolipid biosynthesis and sphingolipid turnover. The results of the present study show that fumonisins B1 and B2 inhibit proliferation and are cytotoxic to LLC-PK1 cells. Concentrations of fumonisin B1 and B2 between 10 and 35 microM inhibited cell proliferation, whereas higher concentrations (greater than 35 microM) killed cells. Inhibition of cell proliferation and cell death were preceded by a lag period of at least 24 hr during which cells appeared to be functioning normally. Cells exposed to fumonisin B1 exhibited normal growth kinetics and morphology soon after fumonisin B1 was removed; thus, the effects of fumonisin B1 were reversible. The EC50 for alterations in sphingolipid biosynthesis was 10 to 15 microM. Inhibition of de novo sphingolipid biosynthesis occurred before inhibition of cell proliferation or cytotoxicity, and the dose response for the decrease in the [3H]sphingosine to [3H]sphinganine ratio at 7 hr closely paralleled the dose response for effects on proliferation and cytotoxicity at 3-5 days. In addition, the level of free sphinganine, and to a lesser extent sphingosine, increased in fumonisin-treated cells in a dose-dependent manner. During the 24-hr lag period preceding inhibition of cell proliferation, the free sphinganine content increased by 12,800% in cells exposed to 35 microM fumonisin B1. Whereas a mechanistic relationship between the inhibition of de novo sphingolipid biosynthesis and inhibition of proliferation and cell death has not been demonstrated, the results of this study support the hypothesis that inhibition of de novo sphingolipid biosynthesis is an early event in the toxicity of fumonisins to LLC-PK1 cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585377     DOI: 10.1016/0041-008x(92)90090-f

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  21 in total

1.  In vitro toxicology of fumonisins and the mechanistic implications.

Authors:  W P Norred; E Wang; H Yoo; R T Riley; A H Merrill
Journal:  Mycopathologia       Date:  1992-02       Impact factor: 2.574

2.  Comparative cytotoxicity of fumonisin B1 in two cell lines derived from normal human bronchial epithelial cells using four distinct bioassay techniques.

Authors:  C Lewis; J Smith; J Anderson; R Freshney
Journal:  Mycotoxin Res       Date:  1999-06       Impact factor: 3.833

3.  Leishmania salvage and remodelling of host sphingolipids in amastigote survival and acidocalcisome biogenesis.

Authors:  Kai Zhang; Fong-Fu Hsu; David A Scott; Roberto Docampo; John Turk; Stephen M Beverley
Journal:  Mol Microbiol       Date:  2005-03       Impact factor: 3.501

Review 4.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

5.  Calculated three dimensional structures of the fumonisin B1-4 mycotoxins.

Authors:  R C Beier; M H Elissalde; L H Stanker
Journal:  Bull Environ Contam Toxicol       Date:  1995-04       Impact factor: 2.151

Review 6.  Glucosylceramide in the nervous system--a mini-review.

Authors:  N S Radin
Journal:  Neurochem Res       Date:  1994-05       Impact factor: 3.996

7.  Fumonisin- and AAL-Toxin-Induced Disruption of Sphingolipid Metabolism with Accumulation of Free Sphingoid Bases.

Authors:  H. K. Abbas; T. Tanaka; S. O. Duke; J. K. Porter; E. M. Wray; L. Hodges; A. E. Sessions; E. Wang; A. H. Merrill; R. T. Riley
Journal:  Plant Physiol       Date:  1994-11       Impact factor: 8.340

8.  In vivo effects of fumonisin B1-producing and fumonisin B1-nonproducing Fusarium moniliforme isolates are similar: fumonisins B2 and B3 cause hepato- and nephrotoxicity in rats.

Authors:  K A Voss; R D Plattner; R T Riley; F I Meredith; W P Norred
Journal:  Mycopathologia       Date:  1998       Impact factor: 2.574

9.  Comparative cytotoxicity of fumonisin B1 and moniliformin in chicken primary cell cultures.

Authors:  W Wu; T Liu; R F Vesonder
Journal:  Mycopathologia       Date:  1995-11       Impact factor: 2.574

10.  Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals.

Authors:  Nicholas C Zitomer; Trevor Mitchell; Kenneth A Voss; Genevieve S Bondy; Sarah T Pruett; Ethel C Garnier-Amblard; Lanny S Liebeskind; Hyejung Park; Elaine Wang; M Cameron Sullards; Alfred H Merrill; Ronald T Riley
Journal:  J Biol Chem       Date:  2008-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.